1
|
Cornillon J, Crocchiolo R, Dubois V, Guidicelli G, Jorge-Cordeiro D, Meunier MC, Michiels S, Timmermans A, Villemonteix J, Yakoub-Agha I, Ahmad I. [Unrelated donor selection for allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S1-S13. [PMID: 37690877 DOI: 10.1016/j.bulcan.2023.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 07/18/2023] [Accepted: 07/19/2023] [Indexed: 09/12/2023]
Abstract
The selection of a donor is an essential element in allogeneic hematopoietic stem cell transplantation. In the absence of an HLA-matched related donor, the selection of an unrelated donor is considered, and is currently the most common type of allogenic donor used in practice. Many criteria are considered for the selection when multiple donors are available, particularly in case of partial match. The aim of this workshop is to assist in the selection of an unrelated donor, in keeping with recent data from the literature.
Collapse
Affiliation(s)
- Jérôme Cornillon
- Centre hospitalo-universitaire de Saint-Étienne 42, département d'hématologie et de thérapie cellulaire, Saint-Étienne, France.
| | | | | | | | - Debora Jorge-Cordeiro
- Université Paris-Cité, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Louis, laboratoire d'immunologie, Paris, France
| | - Marie-Christine Meunier
- Hôpital Maisonneuve-Rosemont, Optilab-CHUM, laboratoire de diagnostic moléculaire et cytogénétique, Montréal, Québec, Canada
| | - Sandra Michiels
- Hôpital universitaire de Bruxelles, institut Jules-Bordet, unité de transplantation-hématologie, Bruxelles, Belgique
| | - Aurélie Timmermans
- Hôpital universitaire de Bruxelles, institut Jules-Bordet, unité de transplantation-hématologie, Bruxelles, Belgique
| | - Juliette Villemonteix
- Université Paris-Cité, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Louis, laboratoire d'immunologie, Paris, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, Inserm U1286, Infinite, université de Lille, 59000 Lille, France
| | - Imran Ahmad
- Université de Montréal, hôpital Maisonneuve-Rosemont, institut universitaire d'hématologie-oncologie & de thérapie cellulaire, Montréal, Québec, Canada
| |
Collapse
|
2
|
Villemonteix J, Allain V, Verstraete E, Jorge-Cordeiro D, Socié G, Xhaard A, Feray C, Caillat-Zucman S. HLA-DP diversity is associated with improved response to SARS-Cov-2 vaccine in hematopoietic stem cell transplant recipients. iScience 2023; 26:106763. [PMID: 37168557 PMCID: PMC10132830 DOI: 10.1016/j.isci.2023.106763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 01/26/2023] [Accepted: 04/24/2023] [Indexed: 05/13/2023] Open
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients show lower humoral vaccine responsiveness than immunocompetent individuals. HLA diversity, measured by the HLA evolutionary divergence (HED) metrics, reflects the diversity of the antigenic repertoire presented to T cells, and has been shown to predict response to cancer immunotherapy. We retrospectively investigated the association of HED with humoral response to SARS-CoV-2 vaccine in allo-HSCT recipients. HED was calculated as pairwise genetic distance between alleles at HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 loci in recipients and their donors. Low anti-spike IgG levels (<30 BAU/mL) were associated with short time from allo-SCT and low donor DPB1-HED, mostly related to donor DPB1 homozygosity. The diversity of donor HLA-DP molecules, assessed by heterozygosity or sequence divergence, may thus impact the efficacy of donor-derived CD4 T cells to sustain vaccine-mediated antibody response in allo-HSCT recipients.
Collapse
Affiliation(s)
- Juliette Villemonteix
- Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, 75010 Paris, France
| | - Vincent Allain
- Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, 75010 Paris, France
- INSERM UMR 976, Université Paris Cité, Institut de Recherche Saint-Louis (IRSL), 75010 Paris, France
| | - Emma Verstraete
- Service d'hématologie-greffe, Hôpital Saint-Louis, AP-HP, Université Paris Cité, 75010 Paris, France
| | - Debora Jorge-Cordeiro
- Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, 75010 Paris, France
| | - Gérard Socié
- INSERM UMR 976, Université Paris Cité, Institut de Recherche Saint-Louis (IRSL), 75010 Paris, France
- Service d'hématologie-greffe, Hôpital Saint-Louis, AP-HP, Université Paris Cité, 75010 Paris, France
| | - Alienor Xhaard
- Service d'hématologie-greffe, Hôpital Saint-Louis, AP-HP, Université Paris Cité, 75010 Paris, France
| | - Cyrille Feray
- Centre Hépato-Biliaire, Hôpital Paul-Brousse, AP-HP, Université Paris-Saclay, FHU Hepatinov, 94800 Villejuif, France
- Institut National de la santé et de la recherche médicale (INSERM) UMR-S 1193, 94800 Villejuif, France
| | - Sophie Caillat-Zucman
- Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, 75010 Paris, France
- INSERM UMR 976, Université Paris Cité, Institut de Recherche Saint-Louis (IRSL), 75010 Paris, France
| |
Collapse
|
3
|
Boy M, Bisio V, Zhao LP, Guidez F, Schell B, Lereclus E, Henry G, Villemonteix J, Rodrigues-Lima F, Gagne K, Retiere C, Larcher L, Kim R, Clappier E, Sebert M, Mekinian A, Fain O, Caignard A, Espeli M, Balabanian K, Toubert A, Fenaux P, Ades L, Dulphy N. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation. Nat Commun 2023; 14:588. [PMID: 36737440 PMCID: PMC9898569 DOI: 10.1038/s41467-023-36193-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Accepted: 01/19/2023] [Indexed: 02/05/2023] Open
Abstract
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders, representing high risk of progression to acute myeloid leukaemia, and frequently associated to somatic mutations, notably in the epigenetic regulator TET2. Natural Killer (NK) cells play a role in the anti-leukemic immune response via their cytolytic activity. Here we show that patients with MDS clones harbouring mutations in the TET2 gene are characterised by phenotypic defects in their circulating NK cells. Remarkably, NK cells and MDS clones from the same patient share the TET2 genotype, and the NK cells are characterised by increased methylation of genomic DNA and reduced expression of Killer Immunoglobulin-like receptors (KIR), perforin, and TNF-α. In vitro inhibition of TET2 in NK cells of healthy donors reduces their cytotoxicity, supporting its critical role in NK cell function. Conversely, NK cells from patients treated with azacytidine (#NCT02985190; https://clinicaltrials.gov/ ) show increased KIR and cytolytic protein expression, and IFN-γ production. Altogether, our findings show that, in addition to their oncogenic consequences in the myeloid cell subsets, TET2 mutations contribute to repressing NK-cell function in MDS patients.
Collapse
Affiliation(s)
- Maxime Boy
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France
| | - Valeria Bisio
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France
| | - Lin-Pierre Zhao
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France
| | - Fabien Guidez
- Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Université Paris Cité, Institut de Recherche Saint Louis INSERM UMR_S1131, F-75010, Paris, France
| | - Bérénice Schell
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France
| | - Emilie Lereclus
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France
| | - Guylaine Henry
- Laboratoire d'Immunologie et d'Histocompatibilité, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, F-75010, Paris, France
| | - Juliette Villemonteix
- Laboratoire d'Immunologie et d'Histocompatibilité, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, F-75010, Paris, France
| | | | - Katia Gagne
- Etablissement Français du Sang, Centre Pays de la Loire, F-44011, Nantes, France.,Université de Nantes, INSERM UMR1307, CNRS UMR 6075, CRCI2NA team 12, F-44000, Nantes, France.,LabEx IGO « Immunotherapy, Graft, Oncology », F-44000, Nantes, France.,LabEx Transplantex, Université de Strasbourg, 67000, Strasbourg, France
| | - Christelle Retiere
- Etablissement Français du Sang, Centre Pays de la Loire, F-44011, Nantes, France.,Université de Nantes, INSERM UMR1307, CNRS UMR 6075, CRCI2NA team 12, F-44000, Nantes, France.,LabEx IGO « Immunotherapy, Graft, Oncology », F-44000, Nantes, France.,LabEx Transplantex, Université de Strasbourg, 67000, Strasbourg, France
| | - Lise Larcher
- Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Laboratoire d'Hématologie, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France
| | - Rathana Kim
- Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Laboratoire d'Hématologie, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France
| | - Emmanuelle Clappier
- Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Laboratoire d'Hématologie, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France
| | - Marie Sebert
- Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Department d'Hématologie Sénior, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France.,Université Paris Cité, Institut de Recherche Saint Louis INSERM UMR_944, F-75010, Paris, France
| | - Arsène Mekinian
- Service de Medecine Interne, Hôpital Saint-Antoine, AP-HP, F-75012, Paris, France.,Departement Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, F-75013, Paris, France
| | - Olivier Fain
- Service de Medecine Interne, Hôpital Saint-Antoine, AP-HP, F-75012, Paris, France.,Departement Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, F-75013, Paris, France
| | - Anne Caignard
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France
| | - Marion Espeli
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France
| | - Karl Balabanian
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France
| | - Antoine Toubert
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France.,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Laboratoire d'Immunologie et d'Histocompatibilité, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, F-75010, Paris, France
| | - Pierre Fenaux
- Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Department d'Hématologie Sénior, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France.,Université Paris Cité, Institut de Recherche Saint Louis INSERM UMR_944, F-75010, Paris, France
| | - Lionel Ades
- Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France.,Department d'Hématologie Sénior, Hôpital Saint-Louis, AP-HP, F-75010, Paris, France.,Université Paris Cité, Institut de Recherche Saint Louis INSERM UMR_944, F-75010, Paris, France
| | - Nicolas Dulphy
- Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM UMR_S1160, F-75010, Paris, France. .,Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, F-75010, Paris, France. .,CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, F-75010, Paris, France. .,Laboratoire d'Immunologie et d'Histocompatibilité, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, F-75010, Paris, France.
| |
Collapse
|
4
|
Villemonteix J, Cohen L, Guihot A, Guérin V, Moulin C, Caseris M, Carol A, Bonacorsi S, Carcelain G. Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19. Immun Inflamm Dis 2022; 10:e617. [PMID: 36169252 PMCID: PMC9449588 DOI: 10.1002/iid3.617] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Revised: 03/11/2022] [Accepted: 03/14/2022] [Indexed: 01/08/2023] Open
Abstract
Introduction Methods Results Conclusions
Collapse
Affiliation(s)
- Juliette Villemonteix
- Laboratory of Immunology, Robert Debré Hospital, APHP Université de Paris Paris France
| | - Laure Cohen
- General Pediatrics and Infectious Diseases Department Robert Debré Hospital, APHP Paris France
| | - Amélie Guihot
- Laboratory of Immunology, Pitié‐Salpétrière Hospital, APHP Paris Sorbonne Université Paris France
| | - Valérie Guérin
- Laboratory of Immunology Robert Debré Hospital, APHP Paris France
| | | | - Marion Caseris
- General Pediatrics and Infectious Diseases Department Robert Debré Hospital, APHP Paris France
| | - Agnès Carol
- Laboratory of Microbiology Robert Debré Hospital, APHP Paris France
| | - Stéphane Bonacorsi
- Laboratory of Microbiology, Robert Debré Hospital, APHP Université Paris Cité Paris France
| | - Guislaine Carcelain
- Laboratory of Immunology, Robert Debré Hospital, APHP Université de Paris Paris France
- Unité Inserm U976 Université Paris Cité Paris France
| |
Collapse
|
5
|
Devriese M, Usureau C, Carmagnat M, Villemonteix J, Taupin JL. The novel HLA-C*17:64Q allele characterized by two different sequencing-based typing techniques. HLA 2022; 100:648-649. [PMID: 35979851 DOI: 10.1111/tan.14773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 08/14/2022] [Accepted: 08/16/2022] [Indexed: 11/27/2022]
Abstract
The novel allele HLA-C*17:64Q differs from HLA-C*17:01:01:02 by insertion of a Lysine in exon 2.
Collapse
Affiliation(s)
- Magali Devriese
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France.,INSERM UMR976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
| | - Cedric Usureau
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France.,INSERM UMR976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
| | | | | | - Jean-Luc Taupin
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France.,INSERM UMR976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
| |
Collapse
|
6
|
Le Méné M, Villemonteix J, Jorge-Cordeiro D, Caillat-Zucman S. Characterization of the novel HLA-DQA1*01:81 allele by sequencing-based typing. HLA 2022; 100:181-182. [PMID: 35393739 DOI: 10.1111/tan.14624] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 04/04/2022] [Accepted: 04/05/2022] [Indexed: 11/29/2022]
Abstract
HLA-DQA1*01:81 differs from HLA-DQA1*01:02:01:01 by one nucleotide substitution in codon 153 in exon 3. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Melchior Le Méné
- Laboratoire d'immunologie et d'histocompatibilité, Hôpital Universitaire Saint Louis, APHP, Paris
| | - Juliette Villemonteix
- Laboratoire d'immunologie et d'histocompatibilité, Hôpital Universitaire Saint Louis, APHP, Paris
| | - Débora Jorge-Cordeiro
- Laboratoire d'immunologie et d'histocompatibilité, Hôpital Universitaire Saint Louis, APHP, Paris
| | - Sophie Caillat-Zucman
- Laboratoire d'immunologie et d'histocompatibilité, Hôpital Universitaire Saint Louis, APHP, Paris.,INSERM UMR976, Human Immunology, Pathophysiology and Immunotherapy, Université de Paris-Cité, Paris
| |
Collapse
|
7
|
Fahrner JE, Lahmar I, Goubet AG, Haddad Y, Carrier A, Mazzenga M, Drubay D, Alves Costa Silva C, de Sousa E, Thelemaque C, Melenotte C, Dubuisson A, Geraud A, Ferrere G, Birebent R, Bigenwald C, Picard M, Cerbone L, Lérias JR, Laparra A, Bernard-Tessier A, Kloeckner B, Gazzano M, Danlos FX, Terrisse S, Pizzato E, Flament C, Ly P, Tartour E, Benhamouda N, Meziani L, Ahmed-Belkacem A, Miyara M, Gorochov G, Barlesi F, Trubert A, Ungar B, Estrada Y, Pradon C, Gallois E, Pommeret F, Colomba E, Lavaud P, Deloger M, Droin N, Deutsch E, Gachot B, Spano JP, Merad M, Scotté F, Marabelle A, Griscelli F, Blay JY, Soria JC, Merad M, André F, Villemonteix J, Chevalier MF, Caillat-Zucman S, Fenollar F, Guttman-Yassky E, Launay O, Kroemer G, La Scola B, Maeurer M, Derosa L, Zitvogel L. The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discov 2022; 12:958-983. [PMID: 35179201 PMCID: PMC9394394 DOI: 10.1158/2159-8290.cd-21-1441] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 01/10/2022] [Accepted: 01/31/2022] [Indexed: 01/07/2023]
Abstract
Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized the polarity and specificity of memory T cells directed against SARS-CoV-2 viral lysates and peptides to determine correlates with spontaneous, virus-elicited, or vaccine-induced protection against COVID-19 in disease-free and cancer-bearing individuals. A disbalance between type 1 and 2 cytokine release was associated with high susceptibility to COVID-19. Individuals susceptible to infection exhibited a specific deficit in the T helper 1/T cytotoxic 1 (Th1/Tc1) peptide repertoire affecting the receptor binding domain of the spike protein (S1-RBD), a hotspot of viral mutations. Current vaccines triggered Th1/Tc1 responses in only a fraction of all subject categories, more effectively against the original sequence of S1-RBD than that from viral variants. We speculate that the next generation of vaccines should elicit Th1/Tc1 T-cell responses against the S1-RBD domain of emerging viral variants. SIGNIFICANCE This study prospectively analyzed virus-specific T-cell correlates of protection against COVID-19 in healthy and cancer-bearing individuals. A disbalance between Th1/Th2 recall responses conferred susceptibility to COVID-19 in both populations, coinciding with selective defects in Th1 recognition of the receptor binding domain of spike. See related commentary by McGary and Vardhana, p. 892. This article is highlighted in the In This Issue feature, p. 873.
Collapse
Affiliation(s)
- Jean-Eudes Fahrner
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.,Transgene S.A., Illkirch-Graffenstaden, France
| | - Imran Lahmar
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Anne-Gaëlle Goubet
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Yacine Haddad
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Agathe Carrier
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Marine Mazzenga
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Damien Drubay
- Gustave Roussy, Villejuif, France.,Département de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Carolina Alves Costa Silva
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Lyon COVID Study Group
- Open Innovation & Partnerships (OIP), bioMérieux S.A., Marcy l'Etoile, France. R&D – Immunoassay, bioMérieux S.A., Marcy l'Etoile, France.,Joint Research Unit Hospices Civils de Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.,International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.,Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| | - Eric de Sousa
- ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, Portugal
| | - Cassandra Thelemaque
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Cléa Melenotte
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.,Aix-Marseille Université, Institut Hospitalo-Universitaire, Institut de Recherche pour le Développement, Assistance Publique – Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille, France
| | - Agathe Dubuisson
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Arthur Geraud
- Gustave Roussy, Villejuif, France.,Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Gladys Ferrere
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Roxanne Birebent
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Camille Bigenwald
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Marion Picard
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Luigi Cerbone
- Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Joana R. Lérias
- ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, Portugal
| | - Ariane Laparra
- Gustave Roussy, Villejuif, France.,Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Alice Bernard-Tessier
- Gustave Roussy, Villejuif, France.,Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Benoît Kloeckner
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Marianne Gazzano
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - François-Xavier Danlos
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Safae Terrisse
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Eugenie Pizzato
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Caroline Flament
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Pierre Ly
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Eric Tartour
- Center of clinical investigations BIOTHERIS, INSERM CIC1428, Gustave Roussy, Villejuif, France.,Department of Immunology, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - Nadine Benhamouda
- Center of clinical investigations BIOTHERIS, INSERM CIC1428, Gustave Roussy, Villejuif, France.,Department of Immunology, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | | | | | - Makoto Miyara
- Univ Paris Est Créteil, INSERM U955, IMRB, Créteil, France
| | - Guy Gorochov
- Univ Paris Est Créteil, INSERM U955, IMRB, Créteil, France
| | - Fabrice Barlesi
- Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.,Sorbonne Université/Institut National de la Santé et de la Recherche Médicale, U1135, Centre d'Immunologie et des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Alexandre Trubert
- Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France
| | - Benjamin Ungar
- Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
| | - Yeriel Estrada
- Department of Dermatology, Center of Excellence in Eczema Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Caroline Pradon
- Gustave Roussy, Villejuif, France.,Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York.,Centre de Ressources Biologiques, ET-EXTRA, Gustave Roussy, Villejuif, France
| | - Emmanuelle Gallois
- Gustave Roussy, Villejuif, France.,Département de Biologie Médicale et Pathologie Médicales, Service de Biochimie, Gustave Roussy, Villejuif, France
| | - Fanny Pommeret
- Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Emeline Colomba
- Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Pernelle Lavaud
- Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Marc Deloger
- Département de Biologie Médicale et Pathologie Médicales, Service de Microbiologie, Gustave Roussy, Villejuif, France
| | - Nathalie Droin
- Gustave Roussy, Plateforme de Bioinformatique, Université Paris-Saclay, INSERM US23, CNRS UMS, Villejuif, France
| | - Eric Deutsch
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Gustave Roussy, Plateforme de génomique, Université Paris-Saclay, INSERM US23, CNRS UMS, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, U1030, Gustave Roussy, Villejuif, France
| | - Bertrand Gachot
- Gustave Roussy, Villejuif, France.,Département de Radiothérapie, Gustave Roussy, Villejuif, France
| | | | - Mansouria Merad
- Gustave Roussy, Villejuif, France.,Department of Medical Oncology, Pitié-Salpétrière Hospital, APHP, Sorbonne Université, Paris, France
| | - Florian Scotté
- Gustave Roussy, Villejuif, France.,Service de Médecine aigue d’Urgence en Cancérologie, Gustave Roussy, Villejuif, France
| | - Aurélien Marabelle
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.,Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.,Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy, Villejuif, France
| | - Frank Griscelli
- Gustave Roussy, Villejuif, France.,Département de Biologie Médicale et Pathologie Médicales, Service de Biochimie, Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale – UMR935/UA9, Université Paris-Saclay, Villejuif, France.,INGESTEM National IPSC Infrastructure, Université de Paris-Saclay, Villejuif, France.,Université de Paris, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| | - Jean-Yves Blay
- Centre Léon Bérard, Lyon, France.,Université Claude Bernard, Lyon, France.,Unicancer, Paris, France
| | - Jean-Charles Soria
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France
| | - Miriam Merad
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Oncological Science, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Fabrice André
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, U981, Gustave Roussy, Villejuif, France
| | - Juliette Villemonteix
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France
| | - Mathieu F. Chevalier
- INSERM UMR 976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
| | - Sophie Caillat-Zucman
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.,INSERM UMR 976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
| | - Florence Fenollar
- IHU Méditérranée Infection, VITROME, IRD, AP-HM, SSA, Aix-Marseille University, Marseille, France
| | - Emma Guttman-Yassky
- Department of Dermatology, Center of Excellence in Eczema Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Odile Launay
- Université de Paris, Inserm CIC 1417, I-Reivac, APHP, Hopital Cochin, Paris, France
| | - Guido Kroemer
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.,Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.,Pôle de Biologie, Hôpital Européen George Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Bernard La Scola
- Institut Hospitalo-Universitaire, Méditerranée Infection, Marseille, France
| | - Markus Maeurer
- ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, Portugal.,Medizinische Klinik, Johannes Gutenberg University Mainz, Germany
| | - Lisa Derosa
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.,Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Laurence Zitvogel
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Gustave Roussy, Villejuif, France.,Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.,Center of clinical investigations BIOTHERIS, INSERM CIC1428, Gustave Roussy, Villejuif, France.,Corresponding Author: Laurence Zitvogel, University Paris-Saclay, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, Villejuif Cedex 94805, France. Phone: 331-4211-5041; E-mail:
| |
Collapse
|
8
|
Jacob V, Usureau C, Villemonteix J, Desoutter J, Guillaume N. Characterization of the novel HLA-DRB1*04:326 allele by next generation sequencing. HLA 2021; 98:236-237. [PMID: 34255440 DOI: 10.1111/tan.14369] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 07/08/2021] [Accepted: 07/09/2021] [Indexed: 11/30/2022]
Abstract
HLA-DRB1*04:326 differs from HLA-DRB1*04:01:01 by one nucleotide substitution in codon 23 in exon 2.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Juliette Villemonteix
- Department of Immunology and Histocompatibility, APHP Hôpital Saint-Louis, Paris, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
9
|
Vauloup-Fellous C, Maylin S, Périllaud-Dubois C, Brichler S, Alloui C, Gordien E, Rameix-Welti MA, Gault E, Moreau F, Fourati S, Challine D, Pawlotsky JM, Houhou-Fidouh N, Damond F, Mackiewicz V, Charpentier C, Méritet JF, Rozenberg F, Podglajen I, Marot S, Petit H, Burrel S, Akhavan S, Leruez-Ville M, Avettand-Fenoel V, Fourgeaud J, Guilleminot T, Gardiennet E, Bonacorsi S, Carol A, Carcelain G, Villemonteix J, Boukli N, Gozlan J, Morand-Joubert L, Legoff J, Delaugerre C, Chaix ML, Roque-Afonso AM, Dortet L, Naas T, Ronat JB, Lepape S, Marcelin AG, Descamps D. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. Eur J Clin Microbiol Infect Dis 2021; 40:2235-2241. [PMID: 33782783 PMCID: PMC8007057 DOI: 10.1007/s10096-021-04232-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Accepted: 03/17/2021] [Indexed: 01/08/2023]
Abstract
We report evaluation of 30 assays' (17 rapid tests (RDTs) and 13 automated/manual ELISA/CLIA assay (IAs)) clinical performances with 2594 sera collected from symptomatic patients with positive SARS-CoV-2 rRT-PCR on a respiratory sample, and 1996 pre-epidemic serum samples expected to be negative. Only 4 RDT and 3 IAs fitted both specificity (> 98%) and sensitivity (> 90%) criteria according to French recommendations. Serology may offer valuable information during COVID-19 pandemic, but inconsistent performances observed among the 30 commercial assays evaluated, which underlines the importance of independent evaluation before clinical implementation.
Collapse
Affiliation(s)
- Christelle Vauloup-Fellous
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France.
| | - Sarah Maylin
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Claire Périllaud-Dubois
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France
| | - Ségolène Brichler
- Laboratoire de Microbiologie Clinique, Centre national de référence des hépatites B, C et Delta, Hôpital Avicenne, Université Paris Nord, 93009, Bobigny, France.,Unité INSERM U955, Créteil, France
| | - Chakib Alloui
- Laboratoire de Microbiologie Clinique, Centre national de référence des hépatites B, C et Delta, Hôpital Avicenne, Université Paris Nord, 93009, Bobigny, France.,Unité INSERM U955, Créteil, France
| | - Emmanuel Gordien
- Laboratoire de Microbiologie Clinique, Centre national de référence des hépatites B, C et Delta, Hôpital Avicenne, Université Paris Nord, 93009, Bobigny, France.,Unité INSERM U955, Créteil, France
| | - Marie-Anne Rameix-Welti
- Laboratoire de Microbiologie, AP-HP. Université Paris Saclay, Hôpital Ambroise Paré, Boulogne-Billancourt, France.,INSERM, Université Paris-Saclay, Université de Versailles St. Quentin, UMR 1173 (2I), Versailles, France
| | - Elyanne Gault
- Laboratoire de Microbiologie, AP-HP. Université Paris Saclay, Hôpital Ambroise Paré, Boulogne-Billancourt, France.,INSERM, Université Paris-Saclay, Université de Versailles St. Quentin, UMR 1173 (2I), Versailles, France
| | - Frédérique Moreau
- Laboratoire de Microbiologie, AP-HP. Université Paris Saclay, Hôpital Ambroise Paré, Boulogne-Billancourt, France.,INSERM, Université Paris-Saclay, Université de Versailles St. Quentin, UMR 1173 (2I), Versailles, France
| | - Slim Fourati
- Department of Virology, Hôpital Henri Mondor, "Viruses, Hepatology, Cancer" Research Unit, Université Paris-Est, INSERM U955, Créteil, France
| | - Dominique Challine
- Department of Virology, Hôpital Henri Mondor, "Viruses, Hepatology, Cancer" Research Unit, Université Paris-Est, INSERM U955, Créteil, France
| | - Jean-Michel Pawlotsky
- Department of Virology, Hôpital Henri Mondor, "Viruses, Hepatology, Cancer" Research Unit, Université Paris-Est, INSERM U955, Créteil, France
| | - Nadhira Houhou-Fidouh
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Florence Damond
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Vincent Mackiewicz
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Charlotte Charpentier
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Jean-François Méritet
- Service de Virologie, Hôpital Cochin - APHP Centre - Université de Paris, Paris, France
| | - Flore Rozenberg
- Service de Virologie, Hôpital Cochin - APHP Centre - Université de Paris, Paris, France
| | - Isabelle Podglajen
- Service de Virologie, Hôpital Européen Georges Pompidou-APHP Centre - Université de Paris, Paris, France
| | - Stéphane Marot
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Heloïse Petit
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Sonia Burrel
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Sepideh Akhavan
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Marianne Leruez-Ville
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Véronique Avettand-Fenoel
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Jacques Fourgeaud
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Tiffany Guilleminot
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Elise Gardiennet
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Stéphane Bonacorsi
- Service de Microbiologie, Hôpital Robert-Debré, Université de Paris, Paris, France
| | - Agnès Carol
- Service de Microbiologie, Hôpital Robert-Debré, Université de Paris, Paris, France
| | - Guislaine Carcelain
- Laboratoire d'immunologie, Hôpital Robert-Debré, Université de Paris, Paris, France
| | | | - Narjis Boukli
- Département de Virologie (Hôpital Saint-Antoine, Tenon, Trousseau), AP-HP Sorbonne Université, INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Joël Gozlan
- Département de Virologie (Hôpital Saint-Antoine, Tenon, Trousseau), AP-HP Sorbonne Université, INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Laurence Morand-Joubert
- Département de Virologie (Hôpital Saint-Antoine, Tenon, Trousseau), AP-HP Sorbonne Université, INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Jérome Legoff
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Constance Delaugerre
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Marie-Laure Chaix
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Ana-Maria Roque-Afonso
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France
| | - Laurent Dortet
- Service de Bactériologie-Hygiène, Hôpital Bicêtre, Inserm U 1184; LabEx LERMIT, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Thierry Naas
- Service de Bactériologie-Hygiène, Hôpital Bicêtre, Inserm U 1184; LabEx LERMIT, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Jean-Baptiste Ronat
- Service de Bactériologie-Hygiène, Hôpital Bicêtre, Inserm U 1184; LabEx LERMIT, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Samuel Lepape
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France
| | - Anne-Geneviève Marcelin
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Diane Descamps
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| |
Collapse
|
10
|
Villemonteix J, Guérin-El Khourouj V, Hugot JP, Giardini C, Carcelain G, Martinez-Vinson C. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases. Biologicals 2021; 70:17-21. [PMID: 33676831 DOI: 10.1016/j.biologicals.2021.02.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 02/10/2021] [Accepted: 02/12/2021] [Indexed: 02/07/2023] Open
Abstract
Many clinical studies in paediatric inflammatory bowel diseases (IBD) use infliximab trough level (IFX-TL) and detection of antibody against infliximab (ATI). Hence, comparison of commercially available assays is needed in paediatric samples to assess their reliability and their comparability. We measured IFX-TL and ATI-TL in sera samples of 53 IBD children using three ELISA kits: Lisa-Tracker® Duo Infliximab (Theradiag®), Ridascreen® IFX monitoring (R-Biopharm®) and Promonitor® IFX (Grifols®). Regarding IFX-TL, median values were comparable (p > 0.05), a good statistical correlation has been observed (0.73 ≤ R2 ≤ 0.85) between tested assays and the Bland-Altman analysis found an excellent agreement with a bias estimated between -0.56 and 0.12 and few values outside the 95% limits of agreement. However, qualitative comparison with therapeutic interval classifications showed some discrepancies (30.2%), mainly due to values near thresholds and more often than not with Theradiag® (22.6%). For ATI, because of non-standardized units, the qualitative comparison found a sensibly good agreement (98.1%). These data show a good agreement of IFX-TL and ATI measurement between three marketed ELISA assays with a small bias obtained. Variations in some results can lead to divergent therapeutic interval classifications and prompt us to be cautious in the interpretation of values near therapeutic thresholds.
Collapse
Affiliation(s)
- Juliette Villemonteix
- Laboratory of Immunology, Hôpital Universitaire Robert Debré, 48, Boulevard Sérurier 75935 PARIS Cedex 19, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.
| | - Valérie Guérin-El Khourouj
- Laboratory of Immunology, Hôpital Universitaire Robert Debré, 48, Boulevard Sérurier 75935 PARIS Cedex 19, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France
| | - Jean-Pierre Hugot
- Department of Paediatric Gastroenterology, Hôpital Universitaire Robert Debré, 48, Boulevard Sérurier 75935 PARIS Cedex 19, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France
| | - Caroline Giardini
- Laboratory of Immunology, Hôpital Universitaire Robert Debré, 48, Boulevard Sérurier 75935 PARIS Cedex 19, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France
| | - Guislaine Carcelain
- Laboratory of Immunology, Hôpital Universitaire Robert Debré, 48, Boulevard Sérurier 75935 PARIS Cedex 19, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France
| | - Christine Martinez-Vinson
- Department of Paediatric Gastroenterology, Hôpital Universitaire Robert Debré, 48, Boulevard Sérurier 75935 PARIS Cedex 19, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France
| |
Collapse
|
11
|
Calvo C, Cabannes‐Hamy A, Adjaoud D, Bruno B, Blanc L, Boissel N, Tabone M, Willson‐Plat G, Villemonteix J, Baruchel A, Brethon B. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory
CD22
‐positive B‐cell acute lymphoblastic leukaemia. Br J Haematol 2020; 190:e53-e56. [DOI: 10.1111/bjh.16732] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Charlotte Calvo
- Pediatric Hematology and Immunology Department Robert Debré University Hospital (APHP and Université de Paris) Paris France
| | - Aurélie Cabannes‐Hamy
- Adolescent and Young Adult Hematology Unit Saint‐Louis Hospital (APHP and Université de Paris) Paris France
| | - Dalila Adjaoud
- Pediatric Oncology and Hematology Department Grenoble University Hospital Grenoble France
| | - Bénédicte Bruno
- Pediatric Hematology Department Lille University Hospital Lille France
| | - Laurence Blanc
- Pediatric Oncology and Hematology Department Poitiers University Hospital Poitiers France
| | - Nicolas Boissel
- Adolescent and Young Adult Hematology Unit Saint‐Louis Hospital (APHP and Université de Paris) Paris France
| | - Marie‐Dominique Tabone
- Pediatric Immunology, Hematology and Oncology Department Trousseau Hospital Paris France
| | - Geneviève Willson‐Plat
- Pediatric Oncology and Hematology Department Toulouse Pediatric Hospital Toulouse France
| | - Juliette Villemonteix
- Immunology Laboratory Robert Debré University Hospital (APHP and Université de Paris) Paris France
| | - André Baruchel
- Pediatric Hematology and Immunology Department Robert Debré University Hospital (APHP and Université de Paris) Paris France
| | - Benoit Brethon
- Pediatric Hematology and Immunology Department Robert Debré University Hospital (APHP and Université de Paris) Paris France
| |
Collapse
|
12
|
Almes M, Villemonteix J, Guérin V, Carcelain G, Hugot JP, Ecochard-Dugelay E. Activation macrophagique chronique chez les enfants en nutrition parentérale prolongée : intérêt du marqueur CD163 soluble. NUTR CLIN METAB 2018. [DOI: 10.1016/j.nupar.2018.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Costopoulos M, Kim R, Choquet S, Maloum K, Houillier C, Algrin C, Settegrana C, Villemonteix J, Brissard M, Quiney C, Bernard S, Davi F, Thieblemont C, Hoang-Xuan K, Leblond V, Merle-Beral H, Le Garff-Tavernier M. Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Semin Hematol 2017; 55:179-181. [PMID: 30502843 DOI: 10.1053/j.seminhematol.2017.06.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 06/30/2017] [Accepted: 06/30/2017] [Indexed: 11/11/2022]
Abstract
We here report for the first time that low levels of interleukin (IL)-10 do not exclude lymphomatous meningitis (LM) in B-cell lymphoproliferative disorders (CLPD). Unexpectedly, IL-10 levels and IL-10:IL-6 ratio in CLPD differed from the levels observed in diffuse large B-cell lymphoma (DLBCL). We report the usefulness of adding the IL-10:IL-6 ratio in order to potentially reveal more aggressive lymphomas: either a transformation or an association with another "hidden" lymphoma such as primary CNS lymphoma (PCNSL).
Collapse
Affiliation(s)
- Myrto Costopoulos
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France; Sorbonne Universités, UPMC, Paris, France; Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders, Paris, France.
| | - Rathana Kim
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France
| | - Sylvain Choquet
- Department of Clinical Hematology, Pitie-Salpetriere Hospital, Paris, France
| | - Karim Maloum
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France
| | | | - Caroline Algrin
- Department of Clinical Hematology, Pitie-Salpetriere Hospital, Paris, France
| | | | | | - Martine Brissard
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France
| | - Claire Quiney
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France
| | - Sophie Bernard
- APHP, Saint-Louis Hospital, Hemato-oncology Department and Paris Cité Sorbonne Diderot 7 University, Paris, France
| | - Frederic Davi
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France; Sorbonne Universités, UPMC, Paris, France; Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders, Paris, France
| | - Catherine Thieblemont
- APHP, Saint-Louis Hospital, Hemato-oncology Department and Paris Cité Sorbonne Diderot 7 University, Paris, France
| | - Khe Hoang-Xuan
- Sorbonne Universités, UPMC, Paris, France; Department of Neuro-Oncology, Pitie-Salpetriere Hospital, Paris, France
| | - Veronique Leblond
- Sorbonne Universités, UPMC, Paris, France; Department of Clinical Hematology, Pitie-Salpetriere Hospital, Paris, France
| | - Helene Merle-Beral
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France; Sorbonne Universités, UPMC, Paris, France; Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders, Paris, France
| | - Magali Le Garff-Tavernier
- Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France; Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders, Paris, France
| |
Collapse
|